ABSTRACT

As pregnant women with COVID-19 have higher mortality rates and as more of them are getting infected, it is crucial to find a more efficacious and safer therapy. Among the various therapies available, intravenous autologous activated platelet-rich plasma (aaPRP) is a potential candidate due to its well-known anti-inflammatory effect and autologous property. To our knowledge as of the writing of this manuscript, this is the first report of intravenous autologous activated platelet-rich plasma therapy in pregnant COVID-19 patients. We reported a case series of pregnant COVID-19 patients, in which two had severe to critical symptoms (age 34 and 26) and two had mild to moderate symptoms (age 41 and 25). The use of intravenous autologous activated platelet-rich plasma was able to ameliorate the hyperinflammatory and hypercoagulability state the patients were in, without any adverse events observed.